{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:52:30Z","timestamp":1780325550925,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"bilateral scientific cooperation between Tunisia and Germany","award":["STC-TUNGER-044"],"award-info":[{"award-number":["STC-TUNGER-044"]}]},{"name":"bilateral scientific cooperation between Tunisia and Germany","award":["STC-TUNGER-044"],"award-info":[{"award-number":["STC-TUNGER-044"]}]},{"name":"bilateral scientific cooperation between Tunisia and Germany","award":["STC-TUNGER-044"],"award-info":[{"award-number":["STC-TUNGER-044"]}]},{"name":"bilateral scientific cooperation between Tunisia and Germany","award":["STC-TUNGER-044"],"award-info":[{"award-number":["STC-TUNGER-044"]}]},{"name":"bilateral scientific cooperation between Tunisia and Germany","award":["STC-TUNGER-044"],"award-info":[{"award-number":["STC-TUNGER-044"]}]},{"name":"bilateral scientific cooperation between Tunisia and Germany","award":["STC-TUNGER-044"],"award-info":[{"award-number":["STC-TUNGER-044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mass vaccination of dogs as important rabies reservoir is proposed to most effectively reduce and eliminate rabies also in humans. However, a minimum coverage of 70% needs to be achieved for control of the disease in zoonotic regions. In numerous developing countries, dog vaccination rate is still dangerously low because of economic constraints and due to a high turnover in dog populations. Improved vaccine production processes may help to alleviate cost and supply limitations. In this work, we studied and optimized the replication and vaccine potency of PV rabies virus strain in the muscovy-duck derived AGE1.CR and AGE1.CR.pIX suspension cell lines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The BHK-21-adapted PV rabies virus strain replicated efficiently in the avian cell lines without requirement for prior passaging.\u00a0CR.pIX was previously shown to augment heat shock responses and supported slightly higher infectious titers compared to the parental CR cell line. Both cell lines allowed replication of rabies virus also in absence of recombinant IGF, the only complex component of the chemically defined medium that was developed for the two cell lines. After scale-up from optimization experiments in shake flask to production in 7-l bioreactors peak virus titers of 2.4\u2009\u00d7\u200910<jats:sup>8<\/jats:sup> FFU\/ml were obtained. The potency of inactivated rabies virus harvest according to the NIH test was 3.5\u00a0IU\/ml. Perfusion with the chemically defined medium during the virus replication phase improved the potency of the vaccine twofold, and increased the number of doses 9.6 fold.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study demonstrates that a rabies vaccine for animal vaccination can be produced efficiently in the AGE1.CR.pIX suspension cell line in a scalable process in chemically defined medium.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12896-022-00747-5","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T10:09:13Z","timestamp":1655460553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of an efficient veterinary rabies vaccine production process in the avian suspension cell line AGE1.CR.pIX"],"prefix":"10.1186","volume":"22","author":[{"given":"Khaled","family":"Trabelsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem Ben","family":"Zakour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Sandig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Rourou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hela","family":"Kallel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"747_CR1","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.vaccine.2017.02.014","volume":"35","author":"RP Lavan","year":"2017","unstructured":"Lavan RP, King AIM, Sutton DJ, Tunceli K. Rationale and support for a one health program for canine vaccination as the most cost-effective means of controlling zoonotic rabies in endemic settings. Vaccine. 2017;35:1668\u201374.","journal-title":"Vaccine"},{"key":"747_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.virusres.2007.02.020","volume":"126","author":"P Coetzee","year":"2007","unstructured":"Coetzee P, Nel LH. Emerging epidemic dog rabies in coastal South Africa: a molecular epidemiological analysis. Virus Res. 2007;126:186\u201395.","journal-title":"Virus Res"},{"key":"747_CR3","first-page":"360","volume":"83","author":"DL Knobel","year":"2005","unstructured":"Knobel DL, Cleaveland S, Coleman PG, F\u00e8vre EM, Meltzer MI, Miranda MEG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005;83:360\u20138.","journal-title":"Bull World Health Organ"},{"key":"747_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/14760584.2019.1627205","volume":"18","author":"CE Rupprecht","year":"2019","unstructured":"Rupprecht CE, Salahuddin N. Current status of human rabies prevention: remaining barriers to global biologics accessibility and disease elimination. Expert Rev Vaccines. 2019;18:629\u201340.","journal-title":"Expert Rev Vaccines"},{"key":"747_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.antiviral.2013.07.004","volume":"100","author":"R Franka","year":"2013","unstructured":"Franka R, Smith TG, Dyer JL, Wu X, Niezgoda M, Rupprecht CE. Current and future tools for global canine rabies elimination. Antiviral Res. 2013;100:220\u20135.","journal-title":"Antiviral Res"},{"key":"747_CR6","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1371\/journal.pntd.0000626","volume":"4","author":"T Lembo","year":"2010","unstructured":"Lembo T, Hampson K, Kaare MT, Ernest E, Knobel D, Kazwala RR, et al. The Feasibility of Canine Rabies Elimination in Africa: Dispelling Doubts with Data. PLoS Negl Trop Dis. 2010;4:e626.","journal-title":"PLoS Negl Trop Dis"},{"key":"747_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/tbed.12168","volume":"62","author":"A Anderson","year":"2015","unstructured":"Anderson A, Shwiff SA. The Cost of canine rabies on four continents. Transbound Emerg Dis. 2015;62:446\u201352.","journal-title":"Transbound Emerg Dis"},{"key":"747_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5372\/1905-7415.0504.075","volume":"5","author":"CM Commentary","year":"2011","unstructured":"Commentary CM. How to eradicate canine rabies: a perspective of historical efforts. Asian Biomed. 2011;5:559\u201368.","journal-title":"Asian Biomed"},{"key":"747_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fvets.2017.00109","volume":"4","author":"LH Taylor","year":"2017","unstructured":"Taylor LH, Wallace RM, Balaram D, Lindenmayer JM, Eckery DC, Mutonono-Watkiss B, et al. The role of dog population management in rabies elimination-a review of current approaches and future opportunities. Front Vet Sci. 2017;4:109.","journal-title":"Front Vet Sci"},{"key":"747_CR10","doi-asserted-by":"publisher","first-page":"e0006387","DOI":"10.1371\/journal.pntd.0006387","volume":"12","author":"AMG Neevel","year":"2018","unstructured":"Neevel AMG, Hemrika T, Claassen E, van de Burgwal LHM. A research agenda to reinforce rabies control: a qualitative and quantitative prioritization. PLoS Negl Trop Dis. 2018;12:e0006387.","journal-title":"PLoS Negl Trop Dis"},{"key":"747_CR11","doi-asserted-by":"publisher","first-page":"e0003447","DOI":"10.1371\/journal.pntd.0003447","volume":"9","author":"T Jibat","year":"2015","unstructured":"Jibat T, Hogeveen H, Mourits MCM. Review on dog rabies vaccination coverage in africa: a question of dog accessibility or cost recovery? PLoS Negl Trop Dis. 2015;9:e0003447.","journal-title":"PLoS Negl Trop Dis"},{"key":"747_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1746-6148-8-236","author":"AS Gsell","year":"2012","unstructured":"Gsell AS, Knobel DL, Cleaveland S, Kazwala RR, Vounatsou P, Zinsstag J. Domestic dog demographic structure and dynamics relevant to rabies control planning in urban areas in Africa: the case of Iringa, Tanzania. BMC Vet Res. 2012. https:\/\/doi.org\/10.1186\/1746-6148-8-236.","journal-title":"BMC Vet Res"},{"key":"747_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.7774\/cevr.2016.5.1.60","volume":"5","author":"S Darkaoui","year":"2016","unstructured":"Darkaoui S, Fassi Fihri O, Schereffer JL, Aboulfidaa N, Wasniewski M, Zouine K, et al. Immunogenicity and efficacy of Rabivac vaccine for animal rabies control in Morocco. Clin Exp Vaccine Res. 2016;5:60.","journal-title":"Clin Exp Vaccine Res"},{"key":"747_CR14","unstructured":"Rupprecht CE, Fooks AR, Abela-Ridder B. Laboratory techniques in rabies, Volume 1. Fifth Edition. World Health Organization; 2018."},{"key":"747_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.vaccine.2008.11.066","volume":"27","author":"I Jordan","year":"2009","unstructured":"Jordan I, Vos A, Beilfu\u00df S, Neubert A, Breul S, Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine. 2009;27:748\u201356.","journal-title":"Vaccine"},{"key":"747_CR16","first-page":"50","volume":"39","author":"I Jordan","year":"2011","unstructured":"Jordan I, Northoff S, Thiele M, Hartmann S, Horn D, H\u00f6wing K, et al. A chemically defined production process for highly attenuated poxviruses. Biol J Int Assoc Biol Stand. 2011;39:50\u20138.","journal-title":"Biol J Int Assoc Biol Stand"},{"key":"747_CR17","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.vaccine.2014.02.016","volume":"32","author":"Y Genzel","year":"2014","unstructured":"Genzel Y, Vogel T, Buck J, Behrendt I, Ramirez DV, Schiedner G, et al. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza a virus production using suspension cells. Vaccine. 2014;32:2770\u201381.","journal-title":"Vaccine"},{"key":"747_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182553","volume":"12","author":"F Tapia","year":"2017","unstructured":"Tapia F, Jordan I, Genzel Y, Reichl U. Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems. PLoS ONE. 2017;12: e0182553.","journal-title":"PLoS ONE"},{"key":"747_CR19","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.vaccine.2017.10.112","volume":"36","author":"D V\u00e1zquez-Ram\u00edrez","year":"2018","unstructured":"V\u00e1zquez-Ram\u00edrez D, Genzel Y, Jordan I, Sandig V, Reichl U. High-cell-density cultivations to increase MVA virus production. Vaccine. 2018;36:3124\u201333.","journal-title":"Vaccine"},{"key":"747_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/03079457.2016.1138280","volume":"45","author":"I Jordan","year":"2016","unstructured":"Jordan I, John K, H\u00f6wing K, Lohr V, Penzes Z, Gubucz-Sombor E, et al. Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines. Avian Pathol. 2016;45:137\u201355.","journal-title":"Avian Pathol"},{"issue":"1","key":"747_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/vaccines7010033","volume":"7","author":"PM Folegatti","year":"2019","unstructured":"Folegatti PM, Bellamy D, Flaxman A, Mair C, Ellis C, Ramon RL, et al. Safety and immunogenicity of the heterosubtypic Influenza A Vaccine MVA-NP+M1 manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines. 2019;7(1):33. https:\/\/doi.org\/10.3390\/vaccines7010033.","journal-title":"Vaccines"},{"key":"747_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy639","author":"N Venkatraman","year":"2018","unstructured":"Venkatraman N, Ndiaye BP, Bowyer G, Wade D, Sridhar S, Wright D, et al. Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen\u2014ChAd3-EBO-Z followed by MVA-EBO-Z in healthy adults in the UK and Senegal. J Infect Dis. 2018. https:\/\/doi.org\/10.1093\/infdis\/jiy639.","journal-title":"J Infect Dis"},{"key":"747_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jbiotec.2011.11.016","volume":"157","author":"CF Shen","year":"2012","unstructured":"Shen CF, Kamen A. Hyperosmotic pressure on HEK 293 cells during the growth phase, but not the production phase, improves adenovirus production. J Biotechnol. 2012;157:228\u201336.","journal-title":"J Biotechnol"},{"key":"747_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/vr.g4996","volume":"175","author":"S Cleaveland","year":"2014","unstructured":"Cleaveland S, Lankester F, Townsend S, Lembo T, Hampson K. Rabies control and elimination: a test case for One Health. Vet Rec. 2014;175:188\u201393.","journal-title":"Vet Rec"},{"key":"747_CR25","first-page":"19","volume":"2","author":"S Nandi","year":"2010","unstructured":"Nandi S, Kumar M. Development in immunoprophylaxis against rabies for animals and humans. Avic J Med Biotechnol. 2010;2:19.","journal-title":"Avic J Med Biotechnol"},{"key":"747_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/trstmh\/trab123","volume":"116","author":"D Nadal","year":"2022","unstructured":"Nadal D, Beeching S, Cleaveland S, Cronin K, Hampson K, Steenson R, et al. Rabies and the pandemic: lessons for one health. Trans R Soc Trop Med Hyg. 2022;116:197\u2013200.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"747_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2471\/BLT.16.173039","volume":"95","author":"JA Kessels","year":"2017","unstructured":"Kessels JA, Recuenco S, Navarro-Vela AM, Deray R, Vigilato M, Ertl H, et al. Pre-exposure rabies prophylaxis: a systematic review. Bull World Health Organ. 2017;95:210-219C.","journal-title":"Bull World Health Organ"},{"issue":"Suppl 1","key":"747_CR28","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1016\/j.vaccine.2019.04.024","volume":"37","author":"N Sreenivasan","year":"2019","unstructured":"Sreenivasan N, Li A, Shiferaw M, Tran CH, Wallace R, Blanton J, et al. Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017\u20132018. Vaccine. 2019;37(Suppl 1):A6-13.","journal-title":"Vaccine"},{"key":"747_CR29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/cid\/ciz056","volume":"69","author":"LM Vos","year":"2019","unstructured":"Vos LM, Bruning AHL, Reitsma JB, Schuurman R, Riezebos-Brilman A, Hoepelman AIM, et al. Rapid molecular tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review of diagnostic accuracy and clinical impact studies. Clin Infect Dis. 2019;69:1243\u201353.","journal-title":"Clin Infect Dis"},{"key":"747_CR30","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1016\/j.vaccine.2012.03.069","volume":"30","author":"SL Davlin","year":"2012","unstructured":"Davlin SL, VonVille HM. Canine rabies vaccination and domestic dog population characteristics in the developing world: a systematic review. Vaccine. 2012;30:3492\u2013502.","journal-title":"Vaccine"},{"key":"747_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/03079457.2014.939941","volume":"43","author":"I M\u00e9sz\u00e1ros","year":"2014","unstructured":"M\u00e9sz\u00e1ros I, T\u00f3th R, B\u00e1lint \u00c1, D\u00e1n \u00c1, Jordan I, Z\u00e1dori Z. Propagation of viruses infecting waterfowl on continuous cell lines of Muscovy duck (Cairina moschata) origin. Avian Pathol. 2014;43:379\u201386.","journal-title":"Avian Pathol"},{"key":"747_CR32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/0264-410X(94)00022-F","volume":"13","author":"P Perrin","year":"1995","unstructured":"Perrin P, Madhusudana S, Gontier-Jallet C, Petres S, Tordo N, Merten O-W. An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system. Vaccine. 1995;13:1244\u201350.","journal-title":"Vaccine"},{"key":"747_CR33","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1292\/jvms.17-0385","volume":"80","author":"INM Astawa","year":"2018","unstructured":"Astawa INM, Agustini NLP, Masa Tenaya IW, Aryawiguna IPGW. Protective antibody response of Balb\/c mice to bali rabies virus isolate propagated in BHK-21 cells. J Vet Med Sci. 2018;80:1596\u2013603.","journal-title":"J Vet Med Sci"},{"key":"747_CR34","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1016\/j.vaccine.2009.05.083","volume":"27","author":"V Lohr","year":"2009","unstructured":"Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: Studies on growth, metabolism and virus propagation. Vaccine. 2009;27:4975\u201382.","journal-title":"Vaccine"},{"key":"747_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymthe.2004.09.018","volume":"11","author":"RJ Parks","year":"2005","unstructured":"Parks RJ. Adenovirus protein IX: a new look at an old protein. Mol Ther J Am Soc Gene Ther. 2005;11:19\u201325.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"747_CR36","doi-asserted-by":"crossref","unstructured":"Latorre V, Mattenberger F, Geller R. Chaperoning the Mononegavirales: Current Knowledge and Future Directions. Viruses. 2018;10.","DOI":"10.20944\/preprints201811.0475.v1"},{"key":"747_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00253-003-1245-3","volume":"61","author":"H Kallel","year":"2003","unstructured":"Kallel H, Rourou S, Majoul S, Loukil H. A novel process for the production of a veterinary rabies vaccine in BHK-21 cells grown on microcarriers in a 20-l bioreactor. Appl Microbiol Biotechnol. 2003;61:441\u20136.","journal-title":"Appl Microbiol Biotechnol"},{"key":"747_CR38","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1016\/j.vaccine.2019.05.092","volume":"37","author":"S Rourou","year":"2019","unstructured":"Rourou S, Ben Zakkour M, Kallel H. Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media. Vaccine. 2019;37:6987\u201395.","journal-title":"Vaccine"},{"key":"747_CR39","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1016\/j.vaccine.2017.03.102","volume":"36","author":"E Petiot","year":"2018","unstructured":"Petiot E, Proust A, Traversier A, Durous L, Dappozze F, Gras M, et al. Influenza viruses production: evaluation of a novel avian cell line DuckCelt\u00ae-T17. Vaccine. 2018;36:3101\u201311.","journal-title":"Vaccine"},{"key":"747_CR40","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","volume":"100","author":"F Tapia","year":"2016","unstructured":"Tapia F, V\u00e1zquez-Ram\u00edrez D, Genzel Y, Reichl U. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production. Appl Microbiol Biotechnol. 2016;100:2121\u201332.","journal-title":"Appl Microbiol Biotechnol"},{"key":"747_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bej.2014.06.001","volume":"90","author":"K Trabelsi","year":"2014","unstructured":"Trabelsi K, Majoul S, Rourou S, Kallel H. Process intensification for an enhanced replication of a newly adapted RM-65 sheep pox virus strain in Vero cells grown in stirred bioreactor. Biochem Eng J. 2014;90:131\u20139.","journal-title":"Biochem Eng J"},{"key":"747_CR42","first-page":"535","volume":"48","author":"JS Smith","year":"1973","unstructured":"Smith JS, Yager PA, Baer GM. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ. 1973;48:535\u201341.","journal-title":"Bull World Health Organ"},{"key":"747_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.072","author":"K Trabelsi","year":"2019","unstructured":"Trabelsi K, Ben Zakour M, Kallel H. Purification of rabies virus produced in Vero cells grown in serum free medium. Vaccine. 2019. https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.072.","journal-title":"Vaccine"},{"key":"747_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0264-410X(93)90343-V","volume":"11","author":"S Morgeaux","year":"1993","unstructured":"Morgeaux S, Tordo N, Gontier C, Perrin P. Beta-Propiolactone treatment impairs the biological activity of residual DNA from BHK-21 cells infected with rabies virus. Vaccine. 1993;11:82\u201390.","journal-title":"Vaccine"},{"key":"747_CR45","unstructured":"Wilbur LA, Aubert M. NIH test for potency. Lab Tech Rabies 4th Edn Ed Meslin FX Kaplan MM Koprowski H Geneva World Health Organ. 1996;:360\u20138."}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-022-00747-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-022-00747-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-022-00747-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T10:09:25Z","timestamp":1655460565000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-022-00747-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1186\/s12896-022-00747-5","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CR.pIX cell line was generated by ProBioGen and published previously. The potency assays were conducted at the animal facility of Institut Pasteur de Tunis; animal experimentation was conducted according to national and international guidelines such as those issued by OLAW (Office of Laboratory Animal Welfare). The Ethics Committee of the Institut Pasteur de Tunis approved the protocol. Experimental research complied with institutional biosafety and biocontainment guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IJ and VS are listed as inventors on patents that protect the anatine cell line (WO 2005\/042728 A3).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}